1. Canada Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Quantum Biopharma Ltd. Subordinate Voting Shares Class B

Quantum Biopharma Ltd. Subordinate Voting Shares Class B

4.51
CAD
+0.41
(+10.00%)
-7.63EPS
39.02MMarket Cap
Nov 06Next Earn
2015 Y
2016 Y
2017 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
0.16
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
-0.25
-0.22
-0.15
-22.08
-134.58
-360.45
-171.62
-65.63
-39.62
-29.39
-12.49
-7.97
-5.34
Free Cash Flow per Basic Share
- -
-0.21
-0.17
-48.89
-133.46
-132.78
-103.25
-39.52
-48.16
-17.78
-6.05
-2.51
-1.17
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-0.44
-0.41
-0.6
77.77
260.94
298.27
123.17
86.98
51.56
21.85
4.99
1.78
1.05
Tangible Book Value per Share
-0.44
-0.41
-0.6
77.77
260.94
159.97
77.63
60.95
31.23
13.01
2.85
0.62
0.48
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
1
1
1
1
3
5
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
-13,585.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
2
4
4
5
3
- -
1
1
Net Income, GAAP
- -
- -
- -
-2
-12
-39
-32
-35
-24
-18
-14
-26
-25
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
-13,585.61
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
- -
- -
3
11
2
21
37
10
7
5
- -
2
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
- -
- -
8
27
36
36
54
31
13
10
5
6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
-69.22
-122.76
-87.62
-78.03
-55.76
-81.78
-114.92
-284.44
-429.58

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
4
6
8
Market Capitalization
30
28
27

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
6
10
10
Cash, Cash Equivalents & STI
2
5
4
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
6
16
8
Payables & Accruals
4
4
3
ST Debt
2
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-1,285.5%
-24.5%
-51.13%
Free Cash Flow
2,925%
-6.57%
19.79%
Net Income, GAAP
1,491.3%
3.47%
84.3%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-3.12
-4.85
-4.17
-2.33
-12.49
2025
-3.47
-3.06
-1.4
-0.78
-7.97
2026
-3.02
-0.49
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Zeeshan Saeed
Full Time Employees
7
Sector
Health technology
Industry
Biotechnology
Address
1 Adelaide Street East Toronto ON Canada M5C 2V9
IPO Date
May 29, 2018
Website
quantumbiopharma.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Quantum BioPharma Ltd. (QNTM) operates as a biopharmaceutical company focused on researching and developing innovative therapies for neurodegenerative, inflammatory, metabolic disorders, and alcohol misuse disorders; its core pipeline includes the lead compound Lucid-MS, a patented new chemical entity in Phase 2 clinical trials targeting myelin degradation in multiple sclerosis; FSD-PEA, preparing for Phase 2 trials for inflammatory diseases such as mast cell activation syndrome; Lucid-PSYCH for major depressive disorder; and unbuzzd, a dietary supplement for alcohol misuse detoxification licensed to Unbuzzd Wellness Inc., with Quantum retaining 20.10% ownership and 7% royalties on sales up to $250 million. The company conducts operations through two segments, Biopharmaceutical Innovation and Strategic Investments, the latter comprising loans secured by residential and commercial properties; it targets patients with neuropsychiatric and neurodegenerative conditions in global markets, primarily from its headquarters in Toronto, Canada, founded in 1998. Recent developments encompass a name change from FSD Pharma Inc. in August 2024; agreements with a contract development and manufacturing organization via subsidiary Huge Biopharma Australia Pty. Ltd. for Lucid-MS oral formulation production; a joint study with Massachusetts General Hospital validating PET imaging for myelin integrity in multiple sclerosis patients; an IND application package preparation with a global CRO for Lucid-MS submission to the U.S. FDA; strengthened third-quarter 2025 liquidity with closed debt and cryptocurrency gains; and positive early safety signals from MS studies, alongside unbuzzd licensee preparations for a potential IPO capital raise of up to $5 million without equity dilution for Quantum shareholders.